Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.

Andrew BlauveltJacob P ThyssenEmma Guttman-YasskyThomas BieberEsther Serra-BaldrichEric SimpsonDavid RosmarinHany ElmaraghyEric MeskimenChitra R NatalieZhuqing LiuChenjia XuEvangeline PierceMaryAnn Morgan-CoxEsther Garcia GilJonathan Ian Silverberg

Published in: The British journal of dermatology (2023)

After a 16-week induction period with lebrikizumab Q2W, lebrikizumab Q2W and Q4W maintained similar improvement of the signs and symptoms of moderate-to-severe AD, with a safety profile consistent with previously published data.

Keyphrases

placebo controlled
phase iii
double blind
atopic dermatitis
phase ii
clinical trial
study protocol
phase ii study
early onset
open label
high intensity
machine learning
electronic health record
sleep quality
data analysis
depressive symptoms